NEW YORK (GenomeWeb) – N-of-One today said that it will provide OncoDNA with clinical interpretation services for its next-generation sequencing and other molecular tests for patients throughout Europe.
Belgium-based OncoDNA provides personalized medicine testing services for cancer patients. One of its tools is the OncoDEEP Clinical Plus test, which is an adapted version of the 400-gene Ion comprehensive cancer panel on the Ion Proton. It also offers a more focused targeted sequencing test, OncoDEEP Dx, using the 48-gene Ion AmpliSeq cancer panel.
N-of-One provides clinical interpretation and insights related to the mutation profile of a tumor identified by sequencing, and it links this knowledge to relevant therapeutic strategies.
Financial and other terms of the agreement with OncoDNA were not disclosed.
Chris Cournoyer, CEO of Lexington, Mass.-based N-of-One, said that the agreement with OncoDNA will "enable broader patient access worldwide to personalized cancer treatment in a scalable, cost-effective manner."